» Articles » PMID: 33335985

Central Pancreatectomy with Roux-en-Y Pancreaticojejunal Anastomosis-Report of Two Cases

Overview
Journal Surg J (N Y)
Specialty General Surgery
Date 2020 Dec 18
PMID 33335985
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

 Central pancreatectomy (CP), a partial resection of the pancreas, is indicated for the excision of neuroendocrine tumors (NETs) of the pancreas, when located at the neck or the proximal body. Specifically, CP is preferable in functional NET and in nonfunctional sized 1 to 2 cm or/with proliferation marker Ki67 < 20% (Grade I/II). Postoperative leakage from the remaining pancreas constitutes the most frequent complication of CP (up to 63%). The aim of our study was to share the experience of our center in CP for NET, with pancreaticojejunal anastomosis.  In 1 year, we performed CP in two patients, following the aforementioned criteria. They presented with tumor of the body of the pancreas, which was found in random check with computed tomography, with negative hormonal blood tests and they underwent magnetic resonance imaging and endoscopic ultrasound/fine-needle biopsy/pathological examination.  The patients underwent CP with Roux-en-Y pancreaticojejunal anastomosis of the distal pancreatic stump and jejunal patch of the proximal pancreatic stump. Histological exam revealed NET sized 2.8 cm and 1.45 cm, Grade I and II, respectively. Postoperatively both patients developed small pancreatic leakage, which did not affect their physical condition and stopped after 20 and 30 days. No one needed pancreatic enzymes supplements or developed new-onset diabetes mellitus.  CP provided adequate, functional remaining pancreatic tissue in both patients. Small leakages were treated conservatively and retreated without septic complications. As a result, CP might be considered as safe and effective technique for pancreatic neck/proximal body NET.

References
1.
Hirono S, Tani M, Kawai M, Ina S, Nishioka R, Miyazawa M . A central pancreatectomy for benign or low-grade malignant neoplasms. J Gastrointest Surg. 2009; 13(9):1659-65. DOI: 10.1007/s11605-009-0934-3. View

2.
Falconi M, Eriksson B, Kaltsas G, Bartsch D, Capdevila J, Caplin M . ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology. 2016; 103(2):153-71. PMC: 4849884. DOI: 10.1159/000443171. View

3.
Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M . The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. Surgery. 2017; 161(3):584-591. DOI: 10.1016/j.surg.2016.11.014. View

4.
Ehehalt F, Saeger H, Schmidt C, Grutzmann R . Neuroendocrine tumors of the pancreas. Oncologist. 2009; 14(5):456-67. DOI: 10.1634/theoncologist.2008-0259. View

5.
Lavu H, Knuth J, Baker M, Shen C, Zyromski N, Schmidt M . Middle segment pancreatectomy can be safely incorporated into a pancreatic surgeon's clinical practice. HPB (Oxford). 2008; 10(6):491-7. PMC: 2597310. DOI: 10.1080/13651820802356580. View